Purchase Price and Allocation. 3.1 The Remuneration payable by the Assignee to the Assignor for the Business Assets shall consist of $97,2190.93( the Cash Component) due to the NIH for previously owed royalty payments and associated legal costs plus and Equity Component consisting of 3,680,000 shares of the Assignee's class A common stock. On or prior to the Closing Date, the Assignee and the Assignor shall enter into a form of subscription agreement in regards to the Equity Component.
Appears in 2 contracts
Sources: Asset Assignment Agreement (Compass Biotechnologies Inc.), Asset Assignment Agreement (Cyplasin Biomedical Ltd.)